Form 4: Hologic Inc. Executive Reports Stock Transactions and Option Grant

A Hologic Inc. executive, Benjamin Jordan Cohn, reported the acquisition of restricted stock units and a stock option grant, along with the disposal of shares to cover tax obligations.

Summary

• Benjamin Jordan Cohn, a Principal Accounting Officer at Hologic Inc., filed a Form 4 detailing changes in his beneficial ownership of company stock.
• On November 7, 2024, 106 shares were disposed of at $79.29 per share to cover tax obligations related to the vesting of restricted stock units.
• On November 8, 2024, another 190 shares were disposed of at $78.76 per share for the same reason.
• On November 11, 2024, 1,180 restricted stock units were acquired, which will vest over three years.
• Also on November 11, 2024, a non-qualified stock option to purchase 3,505 shares was granted, vesting over four years.
• Following these transactions, Mr. Cohn beneficially owns 11,360 shares of common stock and has options for 3,505 shares.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices and does not indicate any significant positive or negative events. The stock transactions are routine and expected.

Positives

• The grant of 1,180 restricted stock units and a stock option for 3,505 shares indicates continued alignment of executive interests with company performance.
• The vesting schedules of the restricted stock units and stock options provide long-term incentives for the executive.

Negatives

• The disposal of 296 shares to cover tax obligations resulted in a slight decrease in direct share ownership.

Risks

• The value of the stock options and restricted stock units is subject to market fluctuations and the company's performance.
• The vesting schedules of the stock options and restricted stock units may not align with the executive's personal financial goals.

Industry Context

This filing is a routine disclosure of executive stock transactions, which is common in publicly traded companies. It reflects standard practices for executive compensation and alignment of interests.

Comparison to Industry Standards

• Stock option and restricted stock unit grants are a common form of executive compensation in the biotechnology and medical device industry, similar to companies like Abbott Laboratories (ABT) and Medtronic (MDT).
• The vesting schedules of three and four years for restricted stock units and stock options, respectively, are typical for long-term incentive plans.
• The disposal of shares to cover tax obligations is a standard practice when restricted stock units vest.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they are related to executive compensation and tax obligations.
• The vesting schedules of the stock options and restricted stock units align executive interests with long-term company performance.

Key Dates

Keywords

Hologic, Stock Options, Restricted Stock Units, Form 4, Executive Compensation, Beneficial Ownership, Stock Transactions